

**Pharmacist Assessment Record (PAR) – Therapeutic Substitution in Extraordinary Circumstances**

|  |  |  |
| --- | --- | --- |
| Patient Name: Click or tap here to enter text. | | Prescription Date: Click or tap to enter a date. |
| Patient Address: Click or tap here to enter text. | | **Patient Phone Number** (Optional)**:**  Click or tap here to enter text. |
| Original Prescription | **Therapeutic Substitution** | |
| Drug Name/Strength/Dosage:  Click or tap here to enter text.  Quantity Prescribed:  Click or tap here to enter text.  Direction for Use:  Click or tap here to enter text. | **Drug Name/Strength/Dosage:**  Click or tap here to enter text.  **Quantity Prescribed:**  Click or tap here to enter text.  **Direction for Use:**  Click or tap here to enter text. | |
| Patient’s Consent Received:  in writing  verbally | | |
| Rationale for Prescribing the Therapeutic Substitution (check all that apply):  Patient’s medication history has been assessed and indicates a chronic stabilized use of the drug  Patient is at immediate risk of interruption of therapy in response to the extenuating circumstances (e.g., drug recall, drug shortage, prescriber not available, problem with administration).  Prescribed at the request of and/or in consultation with the patient  Other factors considered (e.g., clinical, financial needs of patient): Click or tap here to enter text. | | |
| Other Relevant Patient Information (e.g., drug-related problems, actions plans, patient counselling provided):  Patient’s PIP profile reviewed (current and previous medications)  Patient’s eHR reviewed Relevant labs: Click or tap here to enter text.  Patient’s Diagnosis: Click or tap here to enter text.  Diagnosis indicated on official drug monograph:  Yes Continue.  No Refer to primary practitioner. Pharmacists are not permitted to prescribe for off-label use.  Goals of Therapy: Click or tap here to enter text. | | |
| Monitoring and Follow Up Plan: Click or tap here to enter text.  Pharmacist Follows up with Patient: Click or tap here to enter text.  Pharmacist to follow up with patient to ensure safe and effective use of medication in:  The next 72 hours  The next 7 days  Other (best practice time frames specific to the drug): Click or tap here to enter text.  Follow up completed on Click or tap to enter a date.. Details of follow-up: Click or tap here to enter text.  (Report any suspected adverse drug reaction or side-effect to [MedEffect Canada](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html)) Referral to Primary Care Provider: Click or tap here to enter text.  Patient instructed to call primary care provider’s office to make an appointment to review their drug therapy within:  The next 72 hours  The next 7 days  Other (specify details): Click or tap here to enter text. | | |
| Name of prescribing pharmacist: Click or tap here to enter text.  Pharmacy contact information: Click or tap here to enter text. | | |
| Primary care provider notified:  Yes (always required for Therapeutic Substitution PARs)  Name: Click or tap here to enter text. Fax #: Click or tap here to enter text. | | |
| Required Procedures Before Making a Therapeutic Substitution:  Unless previously confirmed, prior to prescribing a therapeutic substitution, the pharmacist must make reasonable efforts to:  Find stock for the patient’s current prescribed drug from other local pharmacies;  Exhaust all options to procure stock from authorized distributors; and  Contact the patient’s primary practitioner to collaborate on an alternative where possible. | | |
| For SCPP auditing purposes:  Emergency provisions used, as declared by the SCPP (check all that apply):  Therapeutic Substitution in Extraordinary Circumstance (Part K, section 10(5)(e))  Back-to-Back pharmacist prescribing (Part K, section 10(5)(b)) 🡪 Not permitted for TS unless otherwise directed by the Registrar  Emergency Provisions not permitted for TS:  Prescribe quantities that exceed limits in the bylaws (Part K Section 10(5)(a))  Prescribe when an active patient-practitioner relationship no longer exists (Part K Section 10(5)(c))  Drug substituted shares the following scientific property with original drug (see [WHO ATC Classification](https://www.whocc.no/atc/structure_and_principles/#Structure)):  Chemical Structure  Mechanism of Action  Therapeutic or Physiologic Effect 🡪 Not permitted for TS outside of a CPA | | |

*Note: This document fulfills the requirements of the Saskatchewan College of Pharmacy Professionals Regulatory Bylaws Part K Section 2(2) and select sections of the* [*SCPP Therapeutic Substitution in Extraordinary Circumstances Policy*](https://saskpharm.ca/document/7367/REF_Therapeutic_Substitutions_in_Extraordinary_Circumstances.pdf)*.*

**RELATED RESOURCES**

1. [Therapeutic Substitution in Extraordinary Circumstances Policy](https://saskpharm.ca/document/7367/REF_Therapeutic_Substitutions_in_Extraordinary_Circumstances.pdf)
2. [Prescriptive Authority Decision Making Framework](https://saskpharm.ca/document/6107/REF_Prescriptive_Authority_Decision_Making_Framework.pdf)
3. [Prescriptive Authority - Pharmacist](https://saskpharm.ca/document/6106/REF_Prescriptive_Authority_Pharmacist.pdf)
4. [Emergency Exemptions for Prescribing Authority](https://scp.in1touch.org/document/5442/REF_Prescribing_Authority_Exemptions.pdf)
5. [Summary of Record Keeping Requirements](https://saskpharm.ca/document/5233/REF_Record_Keeping_Requirements_20190919.pdf) to distinguish between PAR as a ‘prescription’ and PAR as a ‘patient record’